22/03/2021

Reply of the European Union to CL 2021/05/OCS-RVDF on the principles and procedure for the parallel review of a new veterinary drug by JECFA and national regulatory agencies

Mixed Competence

European Union Vote

The European Union and its Member States (EUMS) generally support the proposed principles and procedure for parallel reviews as it could speed up the setting of Codex MRLs for new substances. However, the procedure remains to be tested as, according to JECFA, some data was lacking for the pilot substance selamectin. Moreover, EMA/CVMP did not get an application for setting MRLs for selamectin and therefore the EUMS are not in a position to comment on any specifics.

As an editorial comment, the EUMS note that the document makes a number of references to "products" (eg, in phase 1 "…the product is identified as a candidate."; in phase 2 "At the following CCRVDF meeting, the product would be submitted (…) for inclusion on the prioirity list at CCRVDF (Step 1)."; in phase 3 "JECFA and the national assessor follow their normal processes of assessing the product"). But JECFA undertakes substance evaluations rather than product evaluations and CCRVDF similarly focuses on substances. So it would seem appropriate to refer to substances or veterinary drugs rather than to products.